Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Under the arrangement, prices for GLP-1 drugs—used both for diabetes and obesity—will be slashed for Medicare and Medicaid ...

Medicare will cover weight-loss drugs under a deal between the Trump administration and drugmakers Eli Lilly and Novo Nordisk ...

For years, obesity rates in the US have gone in one direction: up. From the first year it was launched, Gallup’s National ...

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.

A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

A new US government deal with drugmakers Eli Lilly and Novo Nordisk will slash prices for popular weight-loss drugs like ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

A small study helps explain why some people taking Wegovy and similar weight-loss drugs cut back on alcohol, offering insight ...

Many doctors and patients came to believe the rise in obesity may be all but biologically inescapable, despite the grave ...